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Abstract: Migrants from hepatitis B virus (HBV) endemic countries to the European Union/European
Economic Area (EU/EEA) comprise 5.1% of the total EU/EEA population but account for 25% of
total chronic Hepatitis B (CHB) infection. Migrants from high HBV prevalence regions are at the
highest risk for CHB morbidity. These migrants are at risk of late detection of CHB complications;
mortality and onwards transmission. The aim of this systematic review is to evaluate the effectiveness
and cost-effectiveness of CHB screening and vaccination programs among migrants to the EU/EEA.
We found no RCTs or direct evidence evaluating the effectiveness of CHB screening on morbidity and
mortality of migrants. We therefore used a systematic evidence chain approach to identify studies
relevant to screening and prevention programs; testing, treatment, and vaccination. We identified
four systematic reviews and five additional studies and guidelines that reported on screening
and vaccination effectiveness. Studies reported that vaccination programs were highly effective
at reducing the prevalence of CHB in children (RR 0.07 95% CI 0.04 to 0.13) following vaccination.
Two meta-analyses of therapy for chronic HBV infection found improvement in clinical outcomes
and intermediate markers of disease. We identified nine studies examining the cost-effectiveness of
screening for CHB: a strategy of screening and treating CHB compared to no screening. The median
acceptance of HB screening was 87.4% (range 32.3–100%). Multiple studies highlighted barriers to
and the absence of effective strategies to ensure linkage of treatment and care for migrants with CHB.
Int. J. Environ. Res. Public Health 2018, 15, 1898; doi:10.3390/ijerph15091898 www.mdpi.com/journal/ijerph
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In conclusion, screening of high-risk children and adults and vaccination of susceptible children,
combined with treatment of CHB infection in migrants, are promising and cost-effective interventions,
but linkage to treatment requires more attention.
Keywords: HBV; CHB; screening; vaccination; refugees; migrants
1. Introduction
Hepatitis B Virus (HBV) infection can cause acute and chronic hepatitis and lead to life threatening
liver complications including cirrhosis and hepatocellular carcinoma (HCC) [1]. Infection with chronic
hepatitis B (CHB) is typically asymptomatic until health complications develop. However, individuals
with CHB, including asymptomatic cases, can spread the virus through sexual contact, blood-blood
contact, and mother to child transmission [1]. Six percent of the world’s population, approximately
248 million people, are infected with CHB [2]. The global distribution of HBV is highly variable and
regions are characterized by the prevalence of Hepatitis B surface Antigen (HBsAg) as low (<2%),
or endemic (≥2%) [2]. In the European Union/European Economic Area (EU/EEA) an estimated
4–7.5 million people are chronically infected with HBV, with an overall prevalence of 1.12% [3,4].
The majority of countries in the EU/EEA have a low prevalence of HBV infection, although in 2013
five countries had a prevalence >2% [3]. However, CHB infection remains a leading cause of chronic
liver disease and liver cancer in the EU/EEA, and results in significant economic burden and lost
productivity [5,6].
Migrants to the EU/EEA originating from endemic countries suffer a disproportionate burden of
CHB, constituting 5.1% of the population but comprising an estimated 25% (range 14–47%) of total CHB
cases [3]. Antenatal screening programs in the EU/EEA report that migrant women account for 1.0%
to 15.4% of diagnoses of CHB, on average, six times higher than in the general female population [7].
The risk of CHB infection varies amongst different migrant groups. A systematic review of migrants
throughout the world found higher prevalence of CHB in refugees, asylum seekers and migrants
originating from HBV endemic countries [8].
As the majority of cases of CHB are asymptomatic, screening is important to identify individuals
at risk of progression to complications and who are at risk of transmitting the virus. In addition,
screening can identify individuals who are susceptible to infection and would benefit from vaccination.
An effective HB vaccine has been available for nearly four decades and has reduced the incidence
of new infections in the EU/EEA and globally [1,6,9,10]. Universal childhood vaccination against
HB is recommended in 27/31 EU/EEA countries, and all countries recommend vaccination for
children in high-risk groups, including migrants [11]. However, identification of migrants susceptible
to HB infection and delivery of vaccination can be complicated. Internationally, several strategies
for vaccination programs exist including universal childhood vaccination, targeted vaccination of
individuals found to be susceptible to HB, and ring vaccination strategies that prevent the spread
of disease by vaccinating close contacts of known HBV cases [1,12]. Individuals infected during
childhood are at higher risk of developing CHB infection and complications than individually infected
later in life [1,13]. Consequently, prevention of childhood HB infection in migrant communities is a
public health priority.
The World Health Organization (WHO) has set the goal of eliminating CHB as a major public
health threat by 2030 with targets to reduce the incidence of chronic infection by 90% and mortality
by 65% [14]. National programs should include migrants from endemic countries as an important
component of this global strategy. Screening programs for CHB vary by country; at present the majority
of EU/EEA countries do not recommend screening for CHB in migrants [15]. Detecting CHB infections
in migrants from endemic countries and subsequent management including treatment and behavioral
change counselling is likely to decrease the burden of disease in the EU/EEA. In this systematic review,
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we aim to evaluate the effectiveness, costs (resource requirements), and cost-effectiveness of CHB
screening and vaccination programs for migrants to the EU/EEA.
2. Materials and Methods
The Campbell and Cochrane Collaboration Equity Methods Group and review team including
clinicians, public health experts, and researchers from across the EU/EEA used the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach to conduct evidence
reviews. Additional details of the methods can be found in registered systematic review protocol
published in BMJ Open [16].
HBV was selected as a key infectious disease by the review team. The review group followed the
PRISMA reporting guidelines [17] for the reporting of this systematic review. In summary, the review
team developed key research questions (PICO: Population, Intervention, Comparison, Outcome) and
a logic model showing an evidence chain to identify key concepts, to consider the potential role of
indirect evidence related to populations and interventions and to support the formulation of search
strategies [16].
The review teams aimed to answer the following overarching questions:
• Is screening for HBV infection (and subsequent management) associated with decreased morbidity
and mortality in migrant populations?
• What is the effectiveness of HBV vaccination programs in migrant populations?
• What is the cost-effectiveness of screening and vaccination programs for HBV?
We used a combination of key terms including “hepatitis B”, “prevalence”, “screening”, “cost”,
“efficacy”, and “harms”. See Appendix A for the complete list of search terms. Evidence specific to
migrants and the EU/EEA was prioritized, but evidence was considered regardless of the population.
In particularly whenever possible, we sought to include studies examining marginalized communities,
or those with limited health care access, which may be more comparable to migrants than the
general population. Migrants included asylum seekers, refugees, undocumented migrants, and
other foreign-born residents with a focus on those recently arrived.
We searched MEDLINE via OVID and EMBASE, and NHS EED for evidence on the effectiveness
of screening and the cost-effectiveness of screening between 1 January 2010 and 31 December 2016.
Finally, we searched the CEA Registry (Tufts University) and Google Scholar databases for additional
evidence on cost-effectiveness. For the purpose of this review we considered English language
systematic reviews, randomized control trials, and economic studies, evaluating testing, vaccination,
and treatment.
Two independent team members (DM & EA) reviewed the titles and abstracts identified by
the search. Disagreements were resolved by consensus. The full text of identified citations was
then screened for inclusion (DM & EA) with disagreements resolved by consensus. One reviewer
(DM) extracted the data from the included study and a second reviewer (EA) verified the data.
The methodological quality of included studies was assessed using AMSTAR (Assessing the
Methodological Quality of Systematic Reviews) [18].
For evidence around cost-effectiveness, we independently screened and extracted relevant data
from the primary studies including economic study design (e.g., micro-costing study, within-trial
cost-utility analysis, decision-analytic model); the intervention and comparator, the difference in
resource use, costs and cost-effectiveness (e.g., incremental net benefit or incremental cost-effectiveness
ratio), and three specific questions for the GRADE Evidence to Decision table: the size of the
resource requirements, the certainty of evidence around resource requirements, and whether the
cost-effectiveness results favored the intervention or comparison [19]. Finally, we assessed the certainty
of economic evidence in each study using the relevant items from the 1997 Drummond checklist [20].
We assessed the certainty of the quantitative evidence using the GRADE approach.
We incorporated evidence from a review of qualitative studies relating to hepatitis B and migrants.
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On 5 June 2018, we did a pre-publication rapid update search for new high-quality evidence pertaining
to our PICO questions.
3. Results
The search for evidence on effectiveness of screening and vaccination for CHB identified a total of
1829 results. After full text screening, we included four systematic reviews, three guidelines, and two
studies, which met our inclusion criteria. See Figure 1 (PRISMA flow chart) and Table 1. List of included
studies. Studies were excluded for the following reasons: focus on hepatitis C and not hepatitis B,
HCC screening, animal studies and screening for HBV before starting immunosuppressive therapies.
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Figure 1. PRISMA Flow Diagram for Effectiveness of HBV screening and vaccination programs * No
randomized control studies on screening were identified. Included studies were on topics relevant to
the evidence chain (testing, prevalence, vaccination, and treatment).
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Table 1. (a) Characteristics of included studies for screening and vaccine program effectiveness for Hepatitis B Virus.
Study Quality Type of Study Population Intervention Results/Outcomes
Should Hepatitis B Virus (HBV) screening be offered to recently arrived migrants to the EU/EEA?
Chou et al. 2014 [21] AMSTAR * 9/11 Systematic Review 12 RCTs
Treatment with Nucelos(t)ide
Analogues (NAs) compared to
placebo
Reduced rate of intermediate outcomes in NA group
(HBV DNA loss, HBeAg loss, Histologic improvement,
HBsAg loss). No significant decrease in HCC incidence.
No increase in significant adverse events in NA group
but higher rates of study withdrawal
Wong et al. 2010 [22] AMSTAR 7/11 Systematic Review 11 RCTs
Treatment with pegylated
interferon alpha compared to
placebo
Decreased rate of Hepatic Events (RR 0.55 95% CI 0.43
to 0.70), cirrhotic complications (RR 0.46 95% CI 0.32 to
0.67) and liver related mortality (RR 0.63 95% CI 0.42 to
0.96) for treatment group
EASL 2017 [23] NA Guideline Current Treatment Guidelines for acute and chronicinfection with hepatitis B for the EU/EEA
ECDC 2016 [3] NA Technical Document EU/EEA Migrants/GeneralPopulation No intervention
5.5% of migrants born in intermediate/high prevalence
countries infected with CHB infection compared to
1.12% in the general population of EU/EEA
Migrants from HBV endemic countries 5.1% of
population of the EU/EEA but 25% (range 14–47%) of
the total number of CHB cases
WHO 2017 [2] NA Guideline Guidelines on hepatitis B testing including informationon implementation of screening programs.
WHO 2015 [1] NA Guideline Guidelines for the prevention, care and treatment ofpersons with chronic hepatitis B infection.
What is the effectiveness of vaccination programs against HBV?
Graham et al. 2013 [24] AMSTAR 4/11 Systematic Review
Australia:
Aboriginal population/general
population
Vaccination with HBV vaccine
compared to no vaccine
Reduced rate of positive HBsAg in post vaccination
cohort 3.96% (95% CI: 3.15–4.77) compared to
pre-vaccination cohort 16.72 (95% CI: 7.38–26.06).
Chang et al. 2009 [25] NA Individual Study Endemic Country Taiwan(Republic of China)
Vaccination with HBV vaccine
compared to no vaccine
Reduced rate of positive HBsAg (RR 0.07 95% CI 0.04 to
0.13) and chronic liver disease mortality (RR 0.34 95%
CI 0.25 to 0.45) in post vaccination cohort
Rossi et al. 2012 [8] AMSTAR 6/11 Systematic Review Global Migrant Population No intervention
Prevalence of CHB higher in refugees and asylum
seekers compared to immigrants (9.6% vs. 5.1%).
39.7% of migrants demonstrated prior immunity to
HBV either through prior infection or vaccination (95%
CI: 35.7–43.9%).
* A Measurement Tool to Assess Systematic Reviews (AMSTAR).
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Table 1. (b) Characteristics of included studies cost-effectiveness of screening for HBV.
Study Certainty of Economic Evidence (Quality) Design Population Intervention Cost-Effectiveness Resource Requirements
What is the cost-effectiveness of screening (and subsequent management) migrants for chronic hepatitis B (CHB)?
Rossi et al. 2013 [26]
Allowance was made for uncertainty in the estimates of costs
and consequences across plausible ranges.
Appropriate statistical analyses (probabilistic sensitivity
analyses (PSA) were performed for costs and consequences.
Justification was provided for key study parameters and
some upper and lower range estimates. Some ranges cited
the data sources; other ranges provided an assumption for
upper and lower limits but no further justification.
The cost-effectiveness results were not very sensitive to
changes in the values. Most of time, the intervention was still
cost-effective. At a standard willingness to pay threshold, the
probability of being cost-effective was 78% (high).
Decision-analytic
Markov model,
results
presented in
Canadian
dollars.
Vaccination
strategies for
newly arrived
adult Canadian
immigrants and
refugees
(i) universal vaccination, (ii)
screening + vaccination
(iii) screening+ treatment
(iv) screening +treatment +
vaccination
(i) and (ii) were dominated by no
intervention
(iii) screening and treatment:
CAN$40,880 per QALY gained vs no
intervention
(iv) screen, treatment, vaccination:
CAN$437,335 per QALY gained vs no
intervention
The intervention has moderate costs.
Categories and volumes of resource
use were not reported separately.
Wong et al. 2011 [27]
All the ranges were provided.
Both one way, and probabilistic sensitivity analyses were
performed.
All data sources for model inputs were provided, with the
exception of reference years for all costs.
The results were sensitive to the progression rate and
discount rate used. The intervention had a 55% probability
of being cost-effective compared to a no screening strategy.
Certainty in the results was deemed to be moderate overall.
Decision-analytic
Markov model;
reported in
Canadian
dollars
Immigrants to
Canada
(i) ‘No screening’;
(ii) ‘Screen and Treat’
(iii) ‘Screen, Treat and
Vaccinate’
ICER for Screen and treat ranged from
CAN$45,221 (Tenofovir, 3% discount)
per QALY gained to CAN$101,513
(Entecavir, 5% discount)
ICER for Screen, treat and vaccinate
ranged from CAN$96,523 (Entecavir,
3% discount) to CAN$3,648,123 per
QALY gained (Tenofovir, 5% discount)
Favours intervention (ii): screen and
treat, CAN$69,209/QALY gained
(cost-effective)
A vaccination
program following the screening
program was not cost-effective
compared with the screen and treat
strategy.
Large costs for strategy ii: screen and
treat if using either Entecavir or
Tenofovir.
Large costs for strategy iii: screen,
treat and vaccinate using Entecavir.
Other interventions had moderate
costs.
Resource use was not quantified
separately.
Hutton et al. 2007 [12]
Allowance for uncertainty was accommodated.
Both one way and PSA were conducted.
All the data sources were provided for ranges used in
sensitivity analyses.
The probability of being cost-effective was 82–85% when the
values of key variables were changed. Therefore the certainty
of the intervention being cost-effective was deemed high.
Decision-analytic
Markov model;
results in US
dollars
Asian and
Pacific Islander
adult
immigrants to
the US
(i) No Screening: universal
vaccination strategy for all
individuals
(ii) Screen, Treat and No
Vaccination: a screen-and-treat
strategy: screen individuals
and treat infected persons;
(iii) Screen, Treat and Vaccinate:
vaccine for non-infected
persons
(iv) Screen, Treat and Ring
Vaccinate: screen for close
contacts and vaccinate
non-infected persons
The screen-and-treat strategy,
intervention (ii) has an
incremental cost-effectiveness ratio of
US$36,088 per QALY gained compared
with the status quo.
Screen and treat and ring vaccinate
strategy, intervention (iv) has a
cost-effectiveness ratio of US$39,903
per QALY gained compared with the
screen-and-treat strategy.
Universal vaccination, intervention (i)
and screen and treat and vaccine were
dominated.
Costs were moderate, ranging from
US$85,000 per person per lifetime with
universal vaccination to US$87,000 per
person per lifetime to screen, treat and
ring vaccinate.
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Table 1. (b) Cont.
Study Certainty of Economic Evidence (Quality) Design Population Intervention Cost-Effectiveness Resource Requirements
What is the cost-effectiveness of screening (and subsequent management) migrants for chronic hepatitis B (CHB)?
Veldhuijzen et al.
2010 [28]
Uncertainty was tested and all ranges were provided
Univariate, multivariate, PSA were conducted.
Data sources for all the ranges were provided
Cost-effectiveness results were robust to changes in
model parameters. The probability of being
cost-effective was 72%; the certainty was deemed
moderate.
Decision-analytic
Markov model;
results reported in
Euros
Migrants to the
Netherlands from
intermediate and high
HBV endemic areas
One-off systematic screening
and subsequent treatment of
eligible patients, compared
with the status quo: i.e.,
existing pregnancy screening,
testing due to medical
complaints, contact tracing,
and checkup for STIs.
Incremental cost-effectiveness ratio
(ICER) of €8966 per QALY gained.
Discounted costs at 4%
and effects at 1.5%, resulted in a
slightly lower ICER of
€8823 per QALY gained.
Status quo had low test costs at €458
while the screen and treat strategy had
a test cost of €15,954. Referral and
follow up costs for the status quo
strategy was €838; while the screen
and treat strategy had a follow up cost
of €3074. i.e., a large difference.
Screening and treatment costs per
person were ~€130 per person.
Rein et al. 2011 [29]
Standard deviations were provided for costs.
Costing study
(exploratory, pilot
study)
Overseas-born
community living in
the US
Screening models:
(i) Community Clinic
(ii) Community Outreach
(iii) Outreach partnership
(iv) Partnership contract
Cost-effectiveness was not reported
Cost per complete screen ranged from
US$40 for the Community Clinic to
US$280 for the Partnership Contract
model. Low costs for Community
based but higher costs for Partnership
model.
The costs per positive person
identified varied from US$609 in the
Community model to US$4657 in the
Partnership model.
Cost per complete screen/cost per
newly identified positive case (adj. for
prevalence):
1) US$40/$854 ($895)
2) US$102/$2641 ($2698)
3) US$280/$6300 ($6013)
4) US$176/$5709 ($5063)
Jazwa et al. 2015 [30]
Allowance was made for uncertainty, all the ranges
were provided.
Not all statistical tests were reported. Univariate
sensitivity analysis was conducted, which is consistent
with the study design (cost benefit study, not
cost-effectiveness).
All the data sources and assumptions were provided.
Not applicable.
Cost-benefit analysis
Refugees to the US;
costs reported in US
dollars
(i) Vaccinate only without HBV
screening
(ii) Screen, then vaccinate or
initiate management
The net benefits of the screen and
vaccinate strategy ranged from US$24
million to US$130 million after 5 years
from program initiation
The cost per refugee for the
vaccination only strategy was low if
the screen rate <70%, however after 10
years, if the screening rate was more
than 70%, the cost of the vaccination
only strategy was moderate:
US$706–$968 per person.
Ruggeri et al. 2011
[31]
Allowance was made for uncertainty, all the ranges
were provided.
Both one way and PSA were conducted.
All the data sources and assumptions were provided.
The results were not sensitive to changes in the model
values. The probability of being cost-effective was
70–98%; the certainty of the results was deemed high.
Decision-analytic
Markov model;
results reported in
Euros
Residents of Italy
(i) Screening of Italian patients
at risk (assumed prevalence of
7%) and treatment of cases
according to protocol;
(ii) compared with no
screening and treatment of
patients with cirrhosis or HCC
ICER of €18,256 per QALY gained
(±€387) for screening compared to no
screening
High costs for the screening strategy:
€67,008 (±€515) per person per year;
Low cost for no screening strategy, but
moderate costs for the screen and treat
strategy. Moderate cost for no
screening strategy: €7939 (±€1679) per
person per year
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Table 1. (b) Cont.
Study Certainty of Economic Evidence (Quality) Design Population Intervention Cost-Effectiveness Resource Requirements
What is the cost-effectiveness of screening (and subsequent management) migrants for chronic hepatitis B (CHB)?
Eckman et al. 2011
[32]
Allowance was made for uncertainty, all the ranges
were provided.
PSA was conducted
All the data sources and assumptions were provided.
The cost-effectiveness results were sensitive to model
parameters including cost of treatment, drug resistance,
and disease prevalence. The probability of the
intervention being CE was 49%; certainty was deemed
moderate.
Decision-analytic
Markov model;
results reported in US
dollars
Asymptomatic
outpatients in the US
Screening for Hepatitis B
surface antigen followed by
treatment of appropriate
patients with
(i) pegylated interferon-a2a for
48 weeks,
(ii) a low-cost nucleoside or
nucleotide agent
with a high rate of developing
viral resistance for 48 weeks,
(iii) prolonged treatment with
low-cost, high-resistance
nucleoside or nucleotide,
(iv) prolonged treatment with a
high-cost nucleoside or
nucleotide with a low rate of
developing viral resistance;
compared with no screening
Intervention (iii) was dominated by
the no screening intervention;
Intervention (ii) and intervention (v)
were dominated by intervention (iv).
Intervention (iv) was cost-effective
with an ICER of US$29,232 per QALY
gained.
Low cost for no screening strategy
US$915 per person per year. Moderate
cost for screen and treat, ranging from
US$1170 (treat with low cost, high
resistance nucleoside) to US$1286
(treat with high cost, low resistance
nucleoside).
Resource use was not reported
separately.
Li et al. 2013 [33]
Allowance was made for uncertainty. All upper bound
and lower bound limits were provided.
Only univariate sensitivity analysis was conducted.
No, justification was provided for the ranges tested for
price of treatment, or probability of disease progression.
The cost-effectiveness results were not sensitive (i.e.,
remained robust) to changes in the values of variables.
Moderate certainty.
Decision-analytic
Markov model;
results reported in US
dollars.
Residents of
Zhoushan Island in
mainland China.
Monitor and treat scenarios in
3 patient groups according to
treatment eligibility,
(1) ineligible
(2) borderline
(3) eligible
compared with natural history
(no screening and no antiviral
treatment of patients with
cirrhosis or HCC)
ICER of the monitor and treat strategy
compared to the natural history was
US$97 per QALY gained for the
ineligible group, US$500/QALY for
the borderline group, US$1131/QALY
for the eligible group.
With a 5% reduction in Entecavir price:
the monitor and treat strategy
becomes cost saving (ICER < 0) in the
ineligible group; the ICER was US$254
for the eligible group, and US$860 for
the eligible group.
With a 50% reduction in Entecavir
price: the monitor and treat strategy
was cost saving for all sub groups:
(ICER < 0).
For the ineligible group: Difference in
costs was small. For example, total
costs per patient per lifetime was
US$21,229 for natural history strategy,
and US$21,550 for Monitor and Treat.
For the borderline group: The
difference in costs was larger. For
natural history strategy, the total costs
= per patient lifetime was US$33,280
while the total cost per patient lifetime
for the monitor and treat strategy was
US$37,043.
For the eligible group: The difference
in costs was largest. With natural
history strategy, total cost per patient
lifetime was US$32,430 while total cost
per patient lifetime for monitor and
treat strategy was US$42,711.
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In a rapid update prior to publication, we identified one additional systematic review examining
the uptake of screening for HBV in migrant communities.
3.1. Effectiveness of Screening for CHB
Screening tests involving serologic markers are considered to have high validity (sensitivity and
specificity of greater than 98% for detecting HBsAg) for the detection of CHB infection [2]. Our review
found evidence of effective treatment options for CHB that reduced disease morbidity and mortality
in specific subsets of patients [22,23]. Treatment guidelines, including whom to treat, when to initiate
therapy and the first line agents vary across the EU/EEA [22]. Addressing optimal treatment for
CHB was outside the scope of this review. However, the presence of effective treatment options
including pegylated IFNα [22] and nucleos(t)ide analogues [21,23] provide indirect evidence that
suggests screening is likely to be worthwhile, at least for high-risk populations.
We identified an additional systematic review examining the uptake of screening for CHB among
migrants [34]. The review identified four studies examining CHB screening in migrants to the EU/EEA.
The median acceptance of HB screening was 87.4% (range 32.3–100%), and 7.3% of migrants were
found to have CHB infection (range 0.35–31.8%). The review identified no studies that had examined
what percent of migrants identified with CHB were linked to follow up and ongoing care.
3.2. Vaccination Against HBV
Despite the inclusion of HB vaccine in many EU/EEA countries National Immunization
Programs (NIP), migrant populations may not have access to vaccines due to arrival after the
age of vaccination in the general population. Our search and selection did not identify studies
examining vaccination programs in migrant populations. However, we did identify evidence from
two childhood vaccination programs, one involving marginalized sub populations, within endemic
HB communities, demonstrating that childhood vaccination programs were effective at preventing
infection. Evidence from a universal infant and childhood vaccination program in Taiwan showed
a dramatic decrease in HBsAg seropositivity (9.8–0.7%) between 1984 and 1999 [35,36]. Similarly, a
review examining the prevalence of HBV in indigenous and non-indigenous people in the Torres Strait
Islands (which is off the coast of mainland Australia) following the implementation of a universal
vaccination program for infants and adolescents in 2000 showed a decrease in prevalence of HB
infection (6.47% overall prevalence pre 2000 to 2.25%). The impact was particularly pronounced for
the indigenous populations who also faced access barriers to health care (16.72% prevalence pre 2000
to 3.96%) [24]. See Table 2 for a summary of evidence for HB vaccination strategies and Box 1 for the
GRADE grades of evidence.
Box 1. GRADE Working Group grades of evidence.
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from
the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially
different from the estimate of effect
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Table 2. GRADE Evidence Profile: Effect of HBV vaccination on preventing HBV infection, chronic liver disease and HCC.
Certainty Assessment Summary of Findings
No of participants
(studies) Follow-up Risk of bias
Inconsistency Indirectness Imprecision Publicationbias
Overall
certainty of
evidence
Study event rates (%) Relative effect (95%
CI)
Anticipated absolute effects
With no vaccine With HBVvaccine
Risk with no
vaccine
Risk difference
with HBV vaccine
HCC mortality
54289638 (1
observational study) serious
a not serious b not serious serious c none Very Low
135/27144819
(0.0%)
20/27144819
(0.0%) RR 0.90 (0.75 to 1.09) 0 per 100,000
0 fewer per 100,000
(0 fewer to 0 fewer)
Liver cancers (except non-hepatocellular carcinoma)
6898803 (1
observational study) serious
a serious b not serious serious c none Very Low
24/3381519
(0.0%)
20/3517284
(0.0%) RR 0.80 (0.42 to 1.48) 1 per 100,000
0 fewer per 100,000
(0 fewer to 0 fewer)
HBsAg carriage
1916 (1 observational
study) serious
d not serious not serious not serious strongassociation e Low 39/559 (7.0%) 9/1357 (0.7%) RR 0.07 (0.04 to 0.13) 6977 per 100,000
6488 fewer per
100,000 (6698 fewer
to 6070 fewer)
Anti-HBc
1916 (1 observational
study) serious
d not serious not serious not serious strongassociation e Low 115/559 (20.6%) 39/1357 (2.9%) RR 0.11 (0.08 to 0.16) 20,572 per 100,000
18,309 fewer per
100,000 (18,927 fewer
to 17,281 fewer)
Chronic Liver Disease
54289638 (1
observational study) serious
a not serious not serious not serious strongassociation Low
407/38702888
(0.0%)
55/15586750
(0.0%) RR 0.34 (0.25 to 0.45) 1 per 100,000
1 fewer per 100,000
(1 fewer to 1 fewer)
HCC Incidence
54289638 (1
observational study) serious
a not serious not serious not serious none Very Low 712/38702888(0.0%)
191/15586750
(0.0%) RR 0.89 (0.75 to 1.04) 2 per 100,000
0 fewer per 100,000
(0 fewer to 0 fewer)
HBsAg (continuous)
1-12 8545 (8
observational studies) serious
a serious f not serious not serious none Very Low
5516 (Number of
Events)
3029 (Number of
Events) N/A
The mean HBsAg
(continuous) ranged
from 5.19–25.99 %
3.96 % lower (3.15
lower to 4.17 lower)
a Cohort Study, downgraded due to risk of bias; b Heterogeneity is not reported; c Large confidence intervals; d Cohort Study, risk of bias was not assessed; e Large effect; f Hetegeniety (I-squared:
94.9%); CI: Confidence interval; RR: Risk ratio.
Bibliography: Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med
2001;135:796-800 Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. NEngl J Med 1997;336:1855-9. Graham S, Guy
RJ, Cowie B, Wand HC, Donovan B, Akre SP, et al. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis.
BMC Infect Dis. 2013 Dec;13(1):403. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: A 20-year follow-up study. J Natl
Cancer Inst. 2009;101(19):1348–55.
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Analysis of children vaccinated against HBV in Taiwan demonstrated a decline in the annual
incidence of HCC in children 6 to 14 years of age from 0.70 per 100,000 children between 1981 and
1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P < 0.01). The corresponding
rates of mortality from HCC also decreased [25]. We found no studies directly examining the impact
of vaccinating susceptible adult migrants against HB.
Surveillance data following vaccination with HBV have not demonstrated significant adverse
events [37,38]. In 43,618 Alaskan Natives who received 101,360 doses of HB vaccine, possible adverse
reactions occurred in 39 persons and none of the adverse reactions were considered severe [38].
3.3. Cost-Effectiveness of Screening and Subsequent Management for Hepatitis B
We retrieved a total of 228 articles from the National Health System Economic Evaluation Database
(NHS EED) and the Cost-Effectiveness Analysis Registry at Tufts University (CEA Tufts), and a further
ten studies from the effectiveness search from the title and abstract screening. After full text review, we
included nine primary studies from our search, see Figure 2 (PRISMA flow chart). Six of the included
studies were specific to migrant populations, one of which was conducted in The Netherlands [28],
while three were from the USA and two from Canada. Nine primary studies compared the costs and
benefits of different strategies including no screening (n = 6); screening and treating (n = 6); screening,
treating, and vaccinating (n = 4); universal vaccination (n = 3), and ring vaccination (n = 1).
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of CHB with Entecavir, resulted in an incremental cost-effectiveness ratio (ICER) of screening and
treatment compared with no formal screening, of €8966 per quality-adjusted life year (QALY) gained,
with the range of €7222 to €15,694 in sensitivity analysis. These values are below the commonly-used
Dutch cost-effectiveness threshold of €20,000 per QALY gained [28].
Among the five studies of migrants to North America, the costs ranged from CAN$6077 [26] to
US$86,620 [12] per person screened (and treated in the event of a positive result), with the majority of
studies estimating program costs of >$20,000 per person per year. Thus, the costs of these interventions
were generally considered moderate. The ICER of screening and treatment for HBV, compared to
no screening, ranged from US$36,088 [12] to CAN$40,880 [28] and CAN$101,513 (€72,508) [27] per
quality-adjusted life year (QALY) gained. Screening was cost-effective at the host countries’ commonly
accepted willingness to pay thresholds. Therefore, all included studies favored screening and treatment
for HBV over the status quo of no (or voluntary) screening. Two studies found that HBV screening
was likely cost-effective for populations with a prevalence of CHB ≥2% [27]. One study of outpatients
to US hospitals found that screening may be cost-effective even in populations with lower than 2%
prevalence (i.e., 0.3%) [28].
3.4. Cost-Effectiveness of Vaccination
Three studies from North America reported the cost-effectiveness of HBV vaccination, either as a
universal strategy or in addition to screening and treatment in mostly migrant populations with the
majority arriving from South Asia and Sub-Saharan Africa. The universal vaccination strategy was
dominated (i.e., slightly more expensive and slightly less effective) than a no screening intervention
in two studies [12,39]. When examining screening for prior immunity and vaccination, all three
studies found that strategies adding vaccination of susceptible migrants were not cost-effective or
were dominated by the screen and treat strategy [12,26,27]. One of the studies, a US study of Asian
and Pacific Islander adult migrants, found that including screening close contacts of infected persons
and vaccinating susceptible contacts was cost-effective with an ICER of $39,903 per QALY gained,
compared to a screen-and-treat strategy (ICER $36,088/QALY) [12].
4. Discussion
Our review found evidence of effective HB vaccination programs for children and adolescents in
endemic communities with limited access to care. In addition, we found evidence for effective
treatments for cases of CHB that decrease long-term complications in a subset of patients with
CHB. A high percentage of migrants to the EU/EEA accept screening for CHB when offered, and
this screening successfully identifies cases. Our review found cost-effectiveness studies examining
the effect of screening migrants and other populations for HBV infection versus no screening on
clinical outcomes.
Our study did not identify any studies examining the impact of vaccination programs on migrant
populations. However, we found evidence that vaccination programs are highly effective at reducing
disease prevalence and some complications in the general population [35]. In addition, evidence
from New Zealand demonstrated that individuals with access barriers to care gain the most from
vaccination programs [24]. Vaccination programs targeting migrant children and adolescents and
efforts to link migrants to existing national vaccination programs would likely confer similar reductions
in disease burden.
More community based and integrated multi-disease screening studies and related
cost-effectiveness studies on migrant populations are required to determine the optimal approach to
improve uptake and linkage to care. Studies in the EU/EEA on migrant groups with a high prevalence
of CHB infection are needed to build trust and knowledge to support the testing approach. Research is
needed to ensure vaccination programs reach all migrant children and youth.
The economic literature suggests that screening programs for HBV to identify susceptible
individuals or cases and provide treatment are highly likely to be cost-effective in populations with a
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prevalence of HBV ≥2%, and may be cost-effective at a prevalence as low as 0.3% [27,28]. This finding
aligns with studies that support screening for Hepatitis C virus. The evidence for cost-effectiveness of
ring vaccination for close contacts is limited, with one study suggesting cost-effectiveness [12].
4.1. Implementation Considerations
Qualitative evidence suggests that implementing screening programs and ensuring linkage to
treatment and care for migrants presents a number of challenges including: limited access to health
care, inability to navigate a complex health care system and cultural and linguistic barriers [40,41].
Migrant populations have identified stigma, lack of access to primary care or testing, and false and
confusing information regarding testing and treatment eligibility as significant barriers to accessing
screening, vaccination, and treatment [42,43]. For example, a study of predominantly Turkish migrants
in the Netherlands found that those who did not speak Dutch were less likely to attend follow up
appointments [41]. Nevertheless, the majority of migrants appear to accept screening when offered
and studies have suggested they would prefer an integrated screening program to test for multiple
diseases simultaneously [43–45].
Migrants and other populations from high CHB prevalence countries would potentially benefit
from CHB screening in opportunistic facility and community based settings [46]. Facility-based testing
occurs when screening is offered to individuals accessing health care for reasons unrelated to HBV.
Two examples of offering opportunistic HBV screening for migrants presenting for unrelated reasons
to primary health care clinics in Italy found that greater than 90% of migrants accepted screening
for HB when offered [47,48]. Community-based screening, in which screening occurs outside health
care facilities and community members participate in the programs design and implementation,
offers an opportunity to screen patients who may not otherwise present for health care, but this
approach is more resource intensive than facility-based testing [46]. A study of Chinese migrants in the
Netherlands offered screening in schools, community centers and churches or at the local public health
clinic. The study screened 1090 of the estimated 8000 Chinese individuals living in Rotterdam over a
3-month period with the majority preferring to be screened in a community setting [49]. However,
in a community based mosque screening program in UK without Pakistani community engagement,
no patients presented for screening [50]. Approaches resulting in low uptake raise concerns about
missing marginalized populations, such as migrants. Strategies to promote successful linkage of cases
to care for migrants with CHB should be a priority for all programs [41,51]. Successful implementation
of HBV screening depends on factors relevant to the local health systems and population. Deciding
on the best way to implement screening programs may fall to local public health officials and health
systems planners.
4.2. Strengths and Weaknesses
Our review has several strengths: the use of a systematic review with a GRADE approach allows
for evaluation of the certainty and strength of the best available evidence. In addition, the vaccination
studies included both CHB prevalent and marginalized populations, such as an indigenous population
in New Zealand.
Our review also has several limitations: we found no systematic reviews or RCTs that directly
examined the efficacy of screening migrants for HBV. Instead, we followed an evidence chain approach
to estimate the effectiveness of testing and the effectiveness of treatment. The evidence for linkage to
HBV care and treatment and existing screening programs for migrants in the EU/EEA was also very
limited. There are evidence gaps within the screening and vaccination programs. While testing and
treatment for CHB were promising, there is an undeniable evidence gap between linkage to care and
treatment for migrants. The vaccination programs that we identified targeted various high-risk and
sometimes marginalized children. Studies on high-risk migrant populations were limited.
The number of cost-effectiveness studies identified was limited and mostly related to migrants
in North America. Economic evidence is most relevant to the health system in which the study was
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undertaken, and therefore, certain economic evidence may not be transferable to EU/EEA. It was not
possible to accurately convert from US or Canadian dollars to Euros, as the reference year for costs
was not adequately reported in all primary studies. In addition, costs may change over time. Not
all economic studies assessed the levels of seroprevalence across plausible ranges in their sensitivity
analyses, limiting the generalizability of the cost-effectiveness results. Furthermore, most studies used
static decision tree models, which assume a constant probability of acquiring an HBV infection, limiting
the model’s ability to accurately predict cost-effectiveness. Test sensitivity and specificity was not
clearly described in some studies. Definitive economic analysis was limited as most included studies
only considered screening for HBV in isolation rather than an integrated multi-disease screening
program for HBV, HCV, and HIV.
5. Conclusions
Migrants arriving or living in the EU/EEA who originate from HBV endemic countries, have
an increased burden of CHB compared to the general population. Screening high-risk migrants for
HBV and offering monitoring and treatment to those found to be chronically infected will offer clinical
benefits. HBV vaccination programs targeting marginalized and high-risk children and adolescents
significantly reduces the prevalence of CHB. A strategy of screening and treating CHB compared to
no screening is likely to be cost-effective. Cost-effectiveness of screening increases with increasing
HB seroprevalence and uptake, but programs may be cost-effective even in lower seroprevalence
groups (<2%). Qualitative evidence suggests that developing screening approaches for migrants will
be challenging as migrants often lack access to primary health care and may face additional barriers to
care. A mixture of vaccination and testing programs, in a variety of settings, with an emphasis on the
linkage of positive cases to care will most likely have the greatest impact.
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Appendix A. Search Terms
Database: Ovid MEDLINE(R) Epub Ahead of Print <May Week 3 2016>, Ovid MEDLINE(R) 1946
to Present with Daily Update.
Search Date: 26 May 2016
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1 exp Hepatitis B/(49954)
2 (CHB or HBV or HepB).mp. (32246)
3 ((hep or hepatitis) adj3 B).mp. (82681)
4 hbsag.tw. (16191)
5 (hbs adj2 ag).tw. (720)
6 hb-s-ag.tw. (24)
7 ((serum or type b) adj2 hepatitis).tw. (3299)
8 or/1–7 (86774)
9 exp Mass Screening/(108496)
10 (screened or screening? or tested or testing or tests).tw. (1733475)
11 Early Diagnosis/(19328)
12 ((case? or early) adj2 (detected or detection? or diagnos$ or discover$)).tw. (153478)
13 exp Population Surveillance/(56663)
14 (disease? adj2 surveillance).tw. (4191)
15 Contact Tracing/ (3561)
16 contact tracing.tw. (1176)
17 or/9–16 (1940435)
18 meta analysis.mp,pt. (96656)
19 review.pt. (2060002)
20 search$.tw. (266555)
21 guideline.pt. (15761)
22 guideline/(15761)
23 guidelines as topic/(34049)
24 practice guideline.pt. (21200)
25 practice guideline/(21200)
26 practice guidelines as topic/(91709)
27 (CPG or CPGs or guidance or guideline? or recommend$ or standard?).ti. (147079)
28 exp clinical pathway/(5268)
29 exp clinical protocol/(139279)
30 ((care or clinical) adj2 pathway?).tw. (5122)
31 or/18-30 (2570832)
32 8 and 17 and 31 (2192)
33 animals/ not (humans/ and animals/) (4214239)
34 32 not 33 (2176)
35 34 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (675)
36 remove duplicates from 35 (reviews and guidelines) (652)
37 exp “costs and cost analysis”/ (197842)
38 cost$.mp. (467557)
39 cost effective$.tw. (83015)
40 cost benefit analys$.mp. (67281)
41 health care costs.mp. (37134)
42 or/37–41 (476890)
43 8 and 17 and 42 (888)
44 animals/not (humans/and animals/)(4214239)
45 43 not 44 (883)
46 45 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (266)
47 remove duplicates from 46 (costing) (254)
Database: Embase <1974 to 2016 May 26>
Search Date: 26 May 2016
——————————————————————————–
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1 exp hepatitis B/(79653)
2 (CHB or HBV or HepB).mp. (53611)
3 ((hep or hepatitis) adj3 B).mp. (132717)
4 hbsag.tw. (24116)
5 (hbs adj2 ag). tw. (1126)
6 hb-s-ag.tw (626)
7 ((serum or type b) adj2 hepatitis).tw. (4201)
8 or/1–7 (140818)
9 exp mass screening/(182894)
10 (screened or screening? or tested or testing or tests).tw. (2429779)
11 anonymous testing/(223)
12 early diagnosis/(83109)
13 ((case? or early) adj2 (detected or detection? or diagnos$ or discover$)).tw. (235744)
14 exp health survey/(184232)
15 (disease? adj2 surveillance).tw. (5252)
16 contact examination/(2867)
17 contact tracing.tw. (1512)
18 or/9-17 (2853474)
19 meta analysis.mp,pt. (163362)
20 review.pt. (2163167)
21 search$.tw. (371891)
22 guideline.pt. (0)
23 guideline/(144)
24 guidelines as topic/(229891)
25 practice guideline.pt. (0)
26 practice guideline/(275498)
27 practice guidelines as topic/(171087)
28 (CPG or CPGs or guidance or guideline? or recommend$ or standard?).ti. (203281)
29 exp clinical pathway/(6983)
30 exp clinical protocol/(75932)
31 ((care or clinical) adj2 pathway?).tw. (9455)
32 or/19-31 (2897811)
33 8 and 18 and 32 (3886)
34 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
(5865316)
35 33 not 34 (3822)
36 (immigra$ or migrant$ or migration$ or refugee$).mp. (337937)
37 35 and 36 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).dd. (68)
38 remove duplicates from 37 (reviews and guidelines) (67)
39 cost effectiveness analysis/(114261)
40 cost.tw. (387424)
41 costs.tw. (208729)
42 or/39-41 (544762)
43 8 and 18 and 42 (1580)
44 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
(5865316)
45 43 not 44 (1556)
46 (immigra$ or migrant$ or migration$ or refugee$).mp. (337937)
47 45 and 46 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).dd. (59)
References
1. World Health Organization (WHO). Guidelines for the Screening, Care and Treatment of Persons with Chronic
Hepatitis C Infection; WHO: Geneva, Switzerland, 2015.
Int. J. Environ. Res. Public Health 2018, 15, 1898 17 of 19
2. World Health Organization. WHOGuidelines on Hepatitis B and C Testing; World Health Organization: Geneva,
Switzerland, 2017.
3. European Centre for Disease Prevention and Control (ECDC). Epidemiological Assessment of Hepatitis B and C
among Migrants in the EU/EEA; ECDC: Stockholm, Sweden, 2016.
4. Hatzakis, A.; Wait, S.; Bruix, J.; Buti, M.; Carballo, M.; Cavaleri, M.; Colombo, M.; Delarocque-Astagneau, E.;
Dusheiko, G.; Esmat, G.; et al. The State of Hepatitis B and C in Europe: Report from the Hepatitis B and C
Summit Conference. J. Viral Hepat. 2011, 18 (Suppl. 1), 1–16. [CrossRef] [PubMed]
5. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU Neighbourhood: Prevalence,
Burden of Disease and Screening Policies; ECDC: Stockhlom, Sweden, 2010.
6. Blachier, M.; Leleu, H.; Peck-Radosavljevic, M.; Valla, D.C.; Roudot-Thoraval, F. The Burden of Liver Disease
in Europe: A Review of Available Epidemiological Data. J. Hepatol. 2013, 58, 593–608. [CrossRef] [PubMed]
7. European Centre for Disease Prevention and Control. Antenatal Screening for HIV, Hepatitis B, Syphilis and
Rubella Susceptibility in the EU/EEA; ECDC: Stockholm, Sweden, 2016.
8. Rossi, C.; Shrier, I.; Marshall, L.; Cnossen, S.; Schwartzman, K.; Klein, M.B.; Schwarzer, G.; Greenaway, C.
Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A
Systematic Review and Meta-Analysis. PLoS ONE 2012, 7, e44611. [CrossRef] [PubMed]
9. Duffell, E.F.; Hedrich, D.; Mardh, O.; Mozalevskis, A. Towards Elimination of Hepatitis B and C in European
Union and European Economic Area Countries: Monitoring the World Health Organization’s Global Health
Sector Strategy Core Indicators and Scaling up Key Interventions. Eurosurveillance 2017, 22, 30476. [CrossRef]
[PubMed]
10. LeFevre, M.L. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S.
Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 2014, 161, 58–66. [CrossRef]
[PubMed]
11. European Centre for Disease Prevention and Control. Vaccine Schedule. Available online: https://vaccine-
schedule.ecdc.europa.eu/ (accessed on 17 August 2018).
12. Hutton, D.W.; Tan, D.; So, S.K.; Brandeau, M.L. Cost-Effectiveness of Screening and Vaccinating Asian and
Pacific Islander Adults for Hepatitis B. Ann. Intern. Med. 2007, 147, 460–469. [CrossRef] [PubMed]
13. Edmunds, W.J.; Medley, G.F.; Nokes, D.J.; Hall, A.J.; Whittle, H.C. The Influence of Age on the Development
of the Hepatitis B Carrier State. Proc. R. Soc. B Biol. Sci. 1993, 253, 197–201. [CrossRef] [PubMed]
14. World Health Organisation. Global Health Sector Strategy on Viral Hepatitis 2016–2021. Towards Ending Viral
Hepatitis; WHO: Geneva, Switzerland, 2016.
15. European Centre for Disease Prevention and Control. Hepatitis B and C Testing Activities, Needs, and Priorities
in the EU/EEA; ECDC: Stockholm, Sweden, 2017.
16. Pottie, K.; Mayhew, A.; Morton, R.; Greenaway, C.; Akl, E.; Rahman, P. Prevention and Assessment of
Infectious Diseases among Children and Adult Migrants Arriving to the European Union/European
Economic Association: A Protocol for a Suite of Systematic Reviews for Public Health and Health Systems.
BMJ Open 2017, 7, e014608. [CrossRef] [PubMed]
17. Moher, D.; Liberati, A.; Tetzlaf, J.; Altman, D.G.; Group, T.P. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [CrossRef] [PubMed]
18. Shea, B.J.; Grimshaw, J.M.; Well, G.A.; Boers, M.; Andersson, N.; Hamel, C.; Porter, A.C.; Tugwell, P.;
Moher, D.; Bouter, L.M. Development of AMSTAR: A Measurement Tool to Assess the Methodological
Quality of Systematic Reviews. BMC Med. Res. Methodol. 2007, 7, 10. [CrossRef] [PubMed]
19. Schünemann, H.J.; Wiercioch, W.; Brozek, J.; Etxeandia-Ikobaltzeta, I.; Mustafa, R.A.; Manja, V.;
Brignardello-Petersen, R.; Neumann, I.; Falavigna, M.; Alhazzani, W.; et al. GRADE Evidence to Decision
(EtD) Frameworks for Adoption, Adaptation, and de Novo Development of Trustworthy Recommendations:
GRADE-ADOLOPMENT. J. Clin. Epidemiol. 2017, 81, 101–110. [CrossRef] [PubMed]
20. Larsson, L.; Hendricksen, C. Health Economics Information Resources: A Self-Study Course: Module 4; U.S.
National Library of Medicine: Bethesda, MD, USA, 2014.
21. Chou, R.; Dana, T.; Bougatsos, C.; Blazina, I.; Khangura, J.; Zakher, B. Screening for Hepatitis B Virus
Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force
Recommendation. Ann. Intern. Med. 2014, 161, 31–45. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 1898 18 of 19
22. Wong, G.L.H.; Yiu, K.K.L.; Wong, V.W.S.; Tsoi, K.K.F.; Chan, H.L.Y. Meta-Analysis: Reduction in Hepatic
Events Following Interferon-Alfa Therapy of Chronic Hepatitis B. Aliment. Pharmacol. Ther. 2010, 32,
1059–1068. [CrossRef] [PubMed]
23. EASL. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J. Hepatol.
2017, 67, 370–398. [CrossRef] [PubMed]
24. Graham, S.; Guy, R.J.; Cowie, B.; Wand, H.C.; Donovan, B.; Akre, S.P.; Ward, J.S. Chronic Hepatitis
B Prevalence among Aboriginal and Torres Strait Islander Australians since Universal Vaccination: A
Systematic Review and Meta-Analysis. BMC Infect. Dis. 2013, 13, 403. [CrossRef] [PubMed]
25. Chang, M.H.; You, S.L.; Chen, C.J.; Liu, C.J.; Lee, C.M.; Lin, S.M.; Chu, H.C.; Wu, T.C.; Yang, S.S.;
Kuo, H.S.; et al. Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year
Follow-up Study. J. Natl. Cancer Inst. 2009, 101, 1348–1355. [CrossRef] [PubMed]
26. Rossi, C.; Schwartzman, K.; Oxlade, O.; Klein, M.B.; Greenaway, C. Hepatitis B Screening and Vaccination
Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis.
PLoS ONE 2013, 8, e78548. [CrossRef] [PubMed]
27. Wong, W.W.L.; Woo, G.; Heathcote, E.J.; Krahn, M. Cost Effectiveness of Screening Immigrants for Hepatitis
B. Liver Int. 2011, 31, 1179–1190. [CrossRef] [PubMed]
28. Veldhuijzen, I.K.; Toy, M.; Hahné, S.J.M.; De Wit, G.A.; Schalm, S.W.; de Man, R.A.; Richardus, J.H. Screening
and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology
2010, 138, 522–530. [CrossRef] [PubMed]
29. Rein, D.B.; Lesesne, S.B.; Smith, B.D.; Weinbaum, C.M. Models of Community-Based Hepatitis B Surface
Antigen Screening Programs in the U.S. and Their Estimated Outcomes and Costs. Public Health Rep. 2011,
126, 560–567. [CrossRef] [PubMed]
30. Jazwa, A.; Coleman, M.S.; Gazmararian, J.; Wingate, L.T.; Maskery, B.; Mitchell, T.; Weinberg, M. Cost-Benefit
Comparison of Two Proposed Overseas Programs for Reducing Chronic Hepatitis B Infection among
Refugees: Is Screening Essential? Vaccine 2015, 33, 1393–1399. [CrossRef] [PubMed]
31. Ruggeri, M.; Cicchetti, A.; Gasbarrini, A. The Cost-Effectiveness of Alternative Strategies against HBV in
Italy. Health Policy 2011, 102, 72–80. [CrossRef] [PubMed]
32. Eckman, M.H.; Kaiser, T.E.; Sherman, K.E. The Cost-Effectiveness of Screening for Chronic Hepatitis B
Infection in the United States. Clin. Infect. Dis. 2011, 52, 1294–1306. [CrossRef] [PubMed]
33. Li, S.; Xie, Q.; Liu, Y.; Toy, M.; Onder, F.O. Cost-Effectiveness of Early Detection of Inactive and Treatment
of Active Cases in a High Endemic Chronic Hepatitis B Region. J. Antivir. Antiretrovir. 2013, 5, 154–159.
[CrossRef]
34. Seedat, F.; Hargreaves, S.; Nellums, L.B.; Ouyang, J.; Brown, M.; Friedland, J.S. How Effective Are Approaches
to Migrant Screening for Infectious Diseases in Europe? A Systematic Review. Lancet Infect. Dis. 2018, 18,
e259–e271. [CrossRef]
35. Chang, M.-H.; Chen, C.-J.; Lai, M.-S.; Hsu, H.-M.; Wu, T.-C.; Kong, M.-S.; Liang, D.-C.; Shau, W.-Y.; Chen, D.-S.
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children.
N. Engl. J. Med. 1997, 336, 1855–1859. [CrossRef] [PubMed]
36. Ni, Y.H.; Chang, M.H.; Huang, L.M.; Chen, H.L.; Hsu, H.Y.; Chiu, T.Y.; Tsai, K.S.; Chen, D.S. Hepatitis B Virus
Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination.
Ann. Intern. Med. 2001, 135, 796–800. [CrossRef] [PubMed]
37. Brown, R.S.; Mcmahon, B.J.; Lok, A.S.F.; Wong, J.B.; Ahmed, A.T.; Mouchli, M.A.; Wang, Z.; Prokop, L.J.;
Murad, M.H.; Mohammed, K. Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy:
A Systematic Review and Meta-Analysis. Hepatology 2016, 63, 319–333. [CrossRef] [PubMed]
38. McMahon, B.J.; Helminiak, C.; Wainwright, R.B.; Bulkow, L.; Trimble, B.A.; Wainwright, K. Frequency of
Adverse Reactions to Hepatitis B Vaccine in 43,618 Persons. Am. J. Med. 1992, 92, 254–256. [CrossRef]
39. Hahné, S.J.; Veldhuijzen, I.K.; Wiessing, L.; Lim, T.-A.; Salminen, M.; van de Laar, M. Infection with
Hepatitis B and C Virus in Europe: A Systematic Review of Prevalence and Cost-Effectiveness of Screening.
BMC Infect. Dis. 2013, 13, 181.
40. Hacker, K.; Anies, M.; Folb, B.L.; Zallman, L. Barriers to Health Care for Undocumented Immigrants:
A Literature Review. Risk Manag. Healthc. Policy 2015, 8, 175–183. [CrossRef] [PubMed]
41. Mostert, M.C.; Richardus, J.H.; De Man, R.A. Referral of Chronic Hepatitis B Patients from Primary to
Specialist Care: Making a Simple Guideline Work. J. Hepatol. 2004, 41, 1026–1030. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 1898 19 of 19
42. Jones, L.; Bates, G.; McCoy, E.; Beynon, C.; McVeigh, J.; Bellis, M. A Systematic Review of the Effectiveness and
Cost-Effectiveness of Interventions Aimed at Raising Awareness and Engaging with Groups Who Are at an Increased
Risk of Hepatitis B and C Infection—Final Report; Liverpool John Moores University: Liverpool, UK, 2012.
43. Seedat, F.; Hargreaves, S.; Friedland, J.S. Engaging New Migrants in Infectious Disease Screening:
A Qualitative Semi-Structured Interview Study of UK Migrant Community Health-Care Leads. PLoS ONE
2014, 9, e108261. [CrossRef] [PubMed]
44. Hargreaves, S.; Seedat, F.; Car, J.; Escombe, R.; Hasan, S.; Eliahoo, J.; Friedland, J.S. Screening for Latent TB,
HIV, and Hepatitis B/C in New Migrants in a High Prevalence Area of London, UK: A Cross-Sectional Study.
BMC Infect. Dis. 2014, 14, 657. [CrossRef] [PubMed]
45. O’Connell, S.; Lillis, D.; Cotter, A.; O’Dea, S.; Tuite, H.; Fleming, C.; Crowley, B.; Fitzgerald, I.; Dalby, L.;
Barry, H.; et al. Opt-out Panel Testing for HIV, Hepatitis B and Hepatitis C in an Urban Emergency
Department: A Pilot Study. PLoS ONE 2016, 11, e0150546. [CrossRef] [PubMed]
46. Robotin, M.C.; George, J. Community-Based Hepatitis B Screening: What Works? Hepatol. Int. 2014, 8,
478–492. [CrossRef] [PubMed]
47. Coppola, N.; Alessio, L.; Gualdieri, L.; Pisaturo, M.; Sagnelli, C.; Caprio, N.; Maffei, R.; Starace, M.;
Angelillo, I.F.; Pasquale, G.; et al. Hepatitis B Virus, Hepatitis C Virus and Human Immunodeficiency
Virus Infection in Undocumented Migrants and Refugees in Southern Italy, January 2012 to June 2013.
Eurosurveillance 2015, 20, 30009. [CrossRef] [PubMed]
48. El-Hamad, I.; Pezzoli, M.C.; Chiari, E.; Scarcella, C.; Vassallo, F.; Puoti, M.; Ciccaglione, A.; Ciccozzi, M.;
Scalzini, A.; Castelli, F. Point-of-Care Screening, Prevalence, and Risk Factors for Hepatitis B Infection among
3728 Mainly Undocumented Migrants from Non-EU Countries in Northern Italy. J. Travel Med. 2015, 22,
78–86. [CrossRef] [PubMed]
49. Veldhuijzen, I.K.; Wolter, R.; Rijckborst, V.; Mostert, M.; Voeten, H.A.; Cheung, Y.; Boucher, C.A.;
Reijnders, J.G.P.; De Zwart, O.; Janssen, H.L.A. Identification and Treatment of Chronic Hepatitis B in
Chinese Migrants: Results of a Project Offering on-Site Testing in Rotterdam, the Netherlands. J. Hepatol.
2012, 57, 1171–1176. [CrossRef] [PubMed]
50. Lewis, H.; Burke, K.; Begum, S.; Ushiro-Limb, I.; Foster, G. What is the best method of case finding for
chronic viral hepatitis in at-risk migrant communities? J. Hepatol. 2012, 56, S351. [CrossRef]
51. Gish, R.G.; Cooper, S. Hepatitis B in the Greater San Francisco Bay Area: An Integrated Programme to
Respond to a Diverse Local Epidemic. J. Viral Hepat. 2011, 18, e40–e51. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
